A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® (Diclofenac Sodium) Gel 3% in the Treatment of Actinic Keratosis

PHASE3CompletedINTERVENTIONAL
Enrollment

476

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Actinic Keratosis
Interventions
DRUG

Diclofenac sodium

Topical administration of approximately 0.5g twice daily to the 25 sq cm treatment area for 60 days.

OTHER

Placebo

Topical administration of approximately 0.5g twice daily to the 25 sq cm treatment area for 60 days.

Trial Locations (31)

Unknown

Investigator Site 23, Fremont

Investigator Site 9, Long Beach

Investigator Site 12, Newport Beach

Investigator Site 2, San Diego

Investigator Site 24, San Ramon

Investigator Site 14, Denver

Investigator Site 17, Denver

Investigator Site 21, Brandon

Investigator Site 25, Dunedin

Investigator Site 20, Fort Myers

Investigator Site 15, Jacksonville

Investigator Site 16, Miami

Investigator Site 6, Ormond Beach

Investigator Site 19, Winter Park

Investigator Site 22, Atlanta

Investigator Site 11, Boise

Investigator Site 8, Arlington Heights

Investigator Site 28, Plainfield

Investigator Site 31, Louisville

Investigator Site 27, Fridley

Investigator Site 13, Bozeman

Investigator Site 26, New Bern

Investigator Site 3, Raleigh

Investigator Site 18, Wilmington

Investigator Site 30, Cincinnati

Investigator Site 1, Hazleton

Investigator Site 5, Clinton

Investigator Site 4, Johnson City

Investigator Site 10, Nashville

Investigator Site 7, West Jordan

Investigator Site 29, Midlothian

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Actavis Inc.

INDUSTRY

NCT01962987 - A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® (Diclofenac Sodium) Gel 3% in the Treatment of Actinic Keratosis | Biotech Hunter | Biotech Hunter